Invivyd announces PEMGARDA commercial launch, 2024 revenue guidance $150M-$200M

Invivyd, Inc.

PEMGARDA now commercially available in the U.S. for COVID-19 PrEP in immunocompromised adults/adolescents.
2024 net product revenue guidance of $150M to $200M.
Expects to end 2024 with at least $55M in cash and cash equivalents.
Received FDA EUA on March 22, 2024; product available for order within two weeks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.